TrialCurveGastrectomy and second-line chemotherapy in advanced gastric cancer: reconstructed Kaplan–Meier curves
Impact of gastrectomy on efficacy and safety of second-line chemotherapy patients with advanced gastric cancer: Exploratory analysis of two randomized phase III trials. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Ann Gastroenterol Surg. 2024 Nov 4;9(3):429–38. doi: 10.1002/ags3.12880 |
|---|---|
| DOI | 10.1002/ags3.12880 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: with gastrectomy 13.7 months; without gastrectomy 9.2 months. Survival at 18 months: with gastrectomy 32%; without gastrectomy 22%. Hazard ratio with gastrectomy vs without gastrectomy 0.58 (95% CI 0.45–0.75).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| with gastrectomy | 187 | 156 | 13.7 |
| without gastrectomy | 103 | 97 | 9.2 |
- with gastrectomy vs without gastrectomy: reconstructed HR 0.58 (95% CI 0.45–0.75)
Landmark survival (reconstructed)
| Time | with gastrectomy | without gastrectomy |
|---|---|---|
| 6 mo | 83.4% | 70.9% |
| 12 mo | 57.2% | 34.9% |
| 18 mo | 32.2% | 22.3% |
| 24 mo | 19.9% | 8.2% |
| 36 mo | 12.6% | 1.2% |
| 48 mo | 6.5% | — |
Checks against the published figure
- with gastrectomy median: printed 13.8, reconstructed 13.7 pass
- without gastrectomy median: printed 9.3, reconstructed 9.19 pass
- hazard ratio (direction inferred): printed 0.59, reconstructed 0.579 pass
Progression-free survival
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: with gastrectomy 4.6 months; without gastrectomy 2.9 months. Survival at 12 months: with gastrectomy 12%; without gastrectomy 3%. Hazard ratio with gastrectomy vs without gastrectomy 0.58 (95% CI 0.45–0.74).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| with gastrectomy | 187 | 175 | 4.6 |
| without gastrectomy | 103 | 98 | 2.9 |
- with gastrectomy vs without gastrectomy: reconstructed HR 0.58 (95% CI 0.45–0.74)
Landmark survival (reconstructed)
| Time | with gastrectomy | without gastrectomy |
|---|---|---|
| 6 mo | 36.4% | 18.0% |
| 12 mo | 12.2% | 3.2% |
| 18 mo | 8.1% | 2.1% |
| 24 mo | 5.9% | 2.1% |
| 36 mo | 4.0% | — |
Checks against the published figure
- with gastrectomy median: printed 4.7, reconstructed 4.64 pass
- without gastrectomy median: printed 2.8, reconstructed 2.94 pass
- hazard ratio (direction inferred): printed 0.58, reconstructed 0.576 pass
Overall survival (IPTW-adjusted)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: with gastrectomy 13.7 months; without gastrectomy 9.9 months. Survival at 18 months: with gastrectomy 32%; without gastrectomy 26%. Hazard ratio with gastrectomy vs without gastrectomy 0.65 (95% CI 0.54–0.77).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| with gastrectomy | 294 | 248 | 13.7 |
| without gastrectomy | 285 | 262 | 9.9 |
- with gastrectomy vs without gastrectomy: reconstructed HR 0.65 (95% CI 0.54–0.77)
Landmark survival (reconstructed)
| Time | with gastrectomy | without gastrectomy |
|---|---|---|
| 6 mo | 83.3% | 69.4% |
| 12 mo | 57.4% | 39.1% |
| 18 mo | 32.4% | 25.9% |
| 24 mo | 19.3% | 9.2% |
| 36 mo | 12.3% | 2.5% |
| 48 mo | 5.9% | — |
Checks against the published figure
- with gastrectomy median: printed 13.8, reconstructed 13.7 pass
- without gastrectomy median: printed 10, reconstructed 9.89 pass
- hazard ratio (direction inferred): printed 0.66, reconstructed 0.646 pass
Progression-free survival (IPTW-adjusted)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: with gastrectomy 4.2 months; without gastrectomy 3.1 months. Survival at 12 months: with gastrectomy 10%; without gastrectomy 5%. Hazard ratio with gastrectomy vs without gastrectomy 0.72 (95% CI 0.60–0.85).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| with gastrectomy | 294 | 278 | 4.2 |
| without gastrectomy | 285 | 267 | 3.1 |
- with gastrectomy vs without gastrectomy: reconstructed HR 0.72 (95% CI 0.60–0.85)
Landmark survival (reconstructed)
| Time | with gastrectomy | without gastrectomy |
|---|---|---|
| 6 mo | 33.3% | 22.2% |
| 12 mo | 10.0% | 5.3% |
| 18 mo | 6.2% | 3.4% |
| 24 mo | 4.8% | 3.4% |
| 36 mo | 3.1% | — |
Checks against the published figure
- with gastrectomy median: printed 4.3, reconstructed 4.17 pass
- without gastrectomy median: printed 3.2, reconstructed 3.15 pass
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.716 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CheckMate 648: Duration of response (per BICR); Overall survival; Progression-free survival (per BICR)
- Neoadjuvant chemoradiotherapy vs adjuvant therapy in ESCC: Disease-free survival; Overall survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
- Chemoradiotherapy with S-1 in older patients with esophageal cancer: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials